CDK Inhibitors for Specialized Operational Environments
Legal Citation
Summary of the Inventive Concept
The inventive concept adapts CDK inhibitors for specific, narrow markets or unique operational environments, such as high-security bioresearch facilities, disaster relief, extreme weather conditions, high-altitude research, and emergency medical response.
Background and Problem Solved
The original patent disclosed CDK inhibitors for general therapeutic use, but did not address the unique challenges and requirements of specialized operational environments. The new inventive concept addresses these limitations by providing tailored solutions for these specific contexts.
Detailed Description of the Inventive Concept
The inventive concept comprises a system, method, composition, or kit that incorporates the CDK inhibitors disclosed in the original patent, adapted for use in specialized operational environments. For example, the system for high-security bioresearch facilities comprises a secure storage unit for storing the compound, while the method for disaster relief includes administering the compound to a patient in need of CDK inhibition and providing a portable medical unit for remote patient care. The composition for extreme weather conditions includes a weather-resistant packaging material, and the kit for high-altitude research includes a portable laboratory unit for on-site analysis.
Novelty and Inventive Step
The new claims are novel and non-obvious compared to the original patent because they introduce specific, specialized variations and niche solutions that were not anticipated or disclosed in the original patent. The inventive step lies in the recognition of the need for tailored CDK inhibitors for unique operational environments and the development of adapted solutions that address these specific challenges.
Alternative Embodiments and Variations
Alternative embodiments and variations of the inventive concept could include adapting the CDK inhibitors for use in other specialized operational environments, such as space exploration, underwater research, or search and rescue operations. Additionally, the inventive concept could be modified to incorporate other therapeutic agents or technologies to enhance its effectiveness in these contexts.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in various industries, including biotechnology, pharmaceuticals, and medical devices. The target market includes organizations and institutions operating in specialized operational environments, such as government agencies, research institutions, and private companies. The inventive concept could also be licensed or partnered with other companies to expand its reach and impact.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical chemistry, specifically CDK inhibitor drug development and specialized medical applications, requiring advanced degrees in organic chemistry, pharmacology, or related biomedical sciences with expertise in drug formulation and targeted therapeutic delivery
Person of Ordinary Skill (PHOSITA) Profile
A research scientist or pharmaceutical engineer with advanced training in medicinal chemistry, capable of understanding molecular structures, drug delivery mechanisms, and adapting pharmaceutical compounds for specialized environments
Obviousness Rationale
A person skilled in the art would recognize that the core CDK inhibitor compound remains unchanged, and the variations represent predictable adaptations of standard pharmaceutical packaging, delivery, and deployment techniques. The specialized environment claims merely represent routine engineering modifications to extend the utility of the original compound. These adaptations would be considered straightforward extensions of the source patent's core pharmaceutical innovation.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,552 |
|---|---|
| Title | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors |
| Assignee(s) | CARRICK THERAPEUTICS LIMITED |